Trial Outcomes & Findings for Study of Safety & Effectiveness of PRESTIGE® LP Cervical Disc vs. Anterior Cervical Fusion in Cervical DDD (NCT NCT00667459)
NCT ID: NCT00667459
Last Updated: 2023-06-06
Results Overview
Rate of overall success is reported as the percentage of participants who met all of the following criteria: 1. Postoperative Neck Disability Index score improvement of at least a 15-points from preoperative; 2. Maintenance or improvement in neurological status; 3. Disc height success which was defined as either the anterior or posterior measurements meeting the criteria of "Postoperative Height - 6 Week Postoperative Height ≥ -2mm"; 4. No serious adverse event classified as implant associated or implant/surgical procedure associated; and 5. No secondary surgical procedure classified as a "failure."
COMPLETED
PHASE3
280 participants
24 months
2023-06-06
Participant Flow
Participant milestones
| Measure |
Investigational
PRESTIGE® LP Cervical Disc
|
Control
Control patients who received ACDF fusion treatment from a previous IDE trial (NCT00642876)
|
|---|---|---|
|
Overall Study
STARTED
|
280
|
265
|
|
Overall Study
COMPLETED
|
272
|
220
|
|
Overall Study
NOT COMPLETED
|
8
|
45
|
Reasons for withdrawal
| Measure |
Investigational
PRESTIGE® LP Cervical Disc
|
Control
Control patients who received ACDF fusion treatment from a previous IDE trial (NCT00642876)
|
|---|---|---|
|
Overall Study
Death
|
0
|
2
|
|
Overall Study
Lost to Follow-up
|
8
|
43
|
Baseline Characteristics
Study of Safety & Effectiveness of PRESTIGE® LP Cervical Disc vs. Anterior Cervical Fusion in Cervical DDD
Baseline characteristics by cohort
| Measure |
Investigational
n=280 Participants
PRESTIGE® LP Cervical Disc
|
Control
n=265 Participants
Control patients who received ACDF fusion treatment from a previous IDE trial (NCT00642876).
|
Total
n=545 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
44.5 years
STANDARD_DEVIATION 8.8 • n=99 Participants
|
43.9 years
STANDARD_DEVIATION 8.8 • n=107 Participants
|
44.2 years
STANDARD_DEVIATION 8.8 • n=206 Participants
|
|
Sex: Female, Male
Female
|
151 Participants
n=99 Participants
|
143 Participants
n=107 Participants
|
294 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
129 Participants
n=99 Participants
|
122 Participants
n=107 Participants
|
251 Participants
n=206 Participants
|
|
Race/Ethnicity, Customized
Caucasian
|
271 participants
n=99 Participants
|
243 participants
n=107 Participants
|
514 participants
n=206 Participants
|
|
Race/Ethnicity, Customized
Black
|
7 participants
n=99 Participants
|
13 participants
n=107 Participants
|
20 participants
n=206 Participants
|
|
Race/Ethnicity, Customized
Asian
|
0 participants
n=99 Participants
|
2 participants
n=107 Participants
|
2 participants
n=206 Participants
|
|
Race/Ethnicity, Customized
Hispanic
|
1 participants
n=99 Participants
|
6 participants
n=107 Participants
|
7 participants
n=206 Participants
|
|
Race/Ethnicity, Customized
Other
|
1 participants
n=99 Participants
|
1 participants
n=107 Participants
|
2 participants
n=206 Participants
|
|
Height
|
67.7 in.
STANDARD_DEVIATION 4.1 • n=99 Participants
|
67.5 in.
STANDARD_DEVIATION 4.2 • n=107 Participants
|
67.6 in.
STANDARD_DEVIATION 4.2 • n=206 Participants
|
|
Weight
|
186.9 lbs.
STANDARD_DEVIATION 45.0 • n=99 Participants
|
184.7 lbs.
STANDARD_DEVIATION 41.5 • n=107 Participants
|
185.8 lbs.
STANDARD_DEVIATION 43.3 • n=206 Participants
|
|
Marital Status
Single
|
40 participants
n=99 Participants
|
32 participants
n=107 Participants
|
72 participants
n=206 Participants
|
|
Marital Status
Married
|
189 participants
n=99 Participants
|
204 participants
n=107 Participants
|
393 participants
n=206 Participants
|
|
Marital Status
Divorced
|
42 participants
n=99 Participants
|
24 participants
n=107 Participants
|
66 participants
n=206 Participants
|
|
Marital Status
Separated
|
7 participants
n=99 Participants
|
3 participants
n=107 Participants
|
10 participants
n=206 Participants
|
|
Marital Status
Widowed
|
2 participants
n=99 Participants
|
2 participants
n=107 Participants
|
4 participants
n=206 Participants
|
|
Education Level
< High School
|
15 participants
n=99 Participants
|
14 participants
n=107 Participants
|
29 participants
n=206 Participants
|
|
Education Level
High School
|
57 participants
n=99 Participants
|
77 participants
n=107 Participants
|
134 participants
n=206 Participants
|
|
Education Level
> High School
|
206 participants
n=99 Participants
|
173 participants
n=107 Participants
|
379 participants
n=206 Participants
|
|
Education Level
Unknown
|
2 participants
n=99 Participants
|
1 participants
n=107 Participants
|
3 participants
n=206 Participants
|
|
Worker's Compensation Case
Yes
|
32 participants
n=99 Participants
|
35 participants
n=107 Participants
|
67 participants
n=206 Participants
|
|
Worker's Compensation Case
No
|
248 participants
n=99 Participants
|
230 participants
n=107 Participants
|
478 participants
n=206 Participants
|
|
Unresolved Spinal Litigation
Yes
|
34 participants
n=99 Participants
|
32 participants
n=107 Participants
|
66 participants
n=206 Participants
|
|
Unresolved Spinal Litigation
No
|
246 participants
n=99 Participants
|
233 participants
n=107 Participants
|
479 participants
n=206 Participants
|
|
Tobacco Used
Yes
|
74 participants
n=99 Participants
|
92 participants
n=107 Participants
|
166 participants
n=206 Participants
|
|
Tobacco Used
No
|
206 participants
n=99 Participants
|
173 participants
n=107 Participants
|
379 participants
n=206 Participants
|
|
Alcohol Used
Yes
|
150 participants
n=99 Participants
|
141 participants
n=107 Participants
|
291 participants
n=206 Participants
|
|
Alcohol Used
No
|
130 participants
n=99 Participants
|
124 participants
n=107 Participants
|
254 participants
n=206 Participants
|
|
Preop Work Status
Yes
|
188 participants
n=99 Participants
|
166 participants
n=107 Participants
|
354 participants
n=206 Participants
|
|
Preop Work Status
No
|
92 participants
n=99 Participants
|
99 participants
n=107 Participants
|
191 participants
n=206 Participants
|
PRIMARY outcome
Timeframe: 24 monthsPopulation: The primary analysis dataset for this study consists of all subjects who received study devices and completed the initial surgical procedures. The analysis was based on the observed data and missing data due to lost-to-follow-ups were imputed. For the primary endpoint, the analysis consists of 226 investigational subjects and 171 control subjects.
Rate of overall success is reported as the percentage of participants who met all of the following criteria: 1. Postoperative Neck Disability Index score improvement of at least a 15-points from preoperative; 2. Maintenance or improvement in neurological status; 3. Disc height success which was defined as either the anterior or posterior measurements meeting the criteria of "Postoperative Height - 6 Week Postoperative Height ≥ -2mm"; 4. No serious adverse event classified as implant associated or implant/surgical procedure associated; and 5. No secondary surgical procedure classified as a "failure."
Outcome measures
| Measure |
Investigational
n=226 Participants
PRESTIGE® LP Cervical Disc
|
Control
n=171 Participants
Control patients who received ACDF fusion treatment from a previous IDE trial (NCT00642876).
|
|---|---|---|
|
Rate of Overall Success
|
70.4 percentage of participants
|
63.2 percentage of participants
|
SECONDARY outcome
Timeframe: 24 monthsPopulation: For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable NDI success status at 24 months, which leads to 270 subjects in the investigational group and 219 subjects in the control group.
Success rate of Neck Disability Index is reported as the percentage of participants whose neck disability index score met: Pre-treatment Score - Post-treatment Score ≥ 15.
Outcome measures
| Measure |
Investigational
n=270 Participants
PRESTIGE® LP Cervical Disc
|
Control
n=219 Participants
Control patients who received ACDF fusion treatment from a previous IDE trial (NCT00642876).
|
|---|---|---|
|
Success Rate of Neck Disability Index
|
87.8 percentage of participants
|
80.8 percentage of participants
|
SECONDARY outcome
Timeframe: 24 monthsPopulation: For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable neurological success status at 24 months, which leads to 270 subjects in the investigational group and 220 subjects in the control group.
Success rate of neurological status is reported as the percentage of participants who met neurological success defined as maintenance or improvement in all sections (motor, sensory, and reflexes) for the time period evaluated. In order for a section to be considered a success, each element in the section must remain the same or improve from the time of the preoperative evaluation to the time period evaluated.
Outcome measures
| Measure |
Investigational
n=270 Participants
PRESTIGE® LP Cervical Disc
|
Control
n=220 Participants
Control patients who received ACDF fusion treatment from a previous IDE trial (NCT00642876).
|
|---|---|---|
|
Success Rate of Neurological Status
|
93.3 percentage of participants
|
83.6 percentage of participants
|
SECONDARY outcome
Timeframe: 24 monthsPopulation: For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable disc height success (FSU success) status at 24 months, which leads to 224 subjects in the investigational group and 164 subjects in the control group.
Disc height was assessed by determining the Functional Spinal Unit (FSU) height. The rate of disc height success is reported as the percentage of participants whose disc height for each level based on either the anterior or posterior measurements met the following criterion: Postoperative Height - 6 Week Postoperative Height \>= -2mm
Outcome measures
| Measure |
Investigational
n=224 Participants
PRESTIGE® LP Cervical Disc
|
Control
n=164 Participants
Control patients who received ACDF fusion treatment from a previous IDE trial (NCT00642876).
|
|---|---|---|
|
Rate of Disc Height Success
|
91.5 percentage of participants
|
95.1 percentage of participants
|
SECONDARY outcome
Timeframe: 24 monthsPopulation: For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable neck pain success status at 24 months, which leads to 270 subjects in the investigational group and 219 subjects in the control group.
Numerical rating scales were used to evaluate pain intensity and frequency. The pain score (0 min, 100 max) was derived by multiplying the numerical rating scores from the pain intensity (0-10, with a score of 0 representing "no pain" and a score of 10 representing "pain as bad as it could be.") and frequency scales (0-10, with a score of 0 being "pain none of the time" and a score of 10 being "pain all of the time"). Neck pain success rate is reported as the percentage of participants whose neck pain improvement met: Preoperative Score - Postoperative Score \> 0.
Outcome measures
| Measure |
Investigational
n=270 Participants
PRESTIGE® LP Cervical Disc
|
Control
n=219 Participants
Control patients who received ACDF fusion treatment from a previous IDE trial (NCT00642876).
|
|---|---|---|
|
Neck Pain Success Rate
|
96.3 percentage of participants
|
97.3 percentage of participants
|
SECONDARY outcome
Timeframe: 24 monthsPopulation: For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable arm pain success status at 24 months, which leads to 268 subjects in the investigational group and 219 subjects in the control group.
Numerical rating scales were used to evaluate pain intensity and frequency. The pain score (0 min, 100 max) was derived by multiplying the numerical rating scores from the pain intensity (0-10, with a score of 0 representing "no pain" and a score of 10 representing "pain as bad as it could be.") and frequency scales (0-10, with a score of 0 being "pain none of the time" and a score of 10 being "pain all of the time"). Arm pain success rate is reported as the percentage of participants whose arm pain improvement met: Preoperative Score - Postoperative Score \> 0.
Outcome measures
| Measure |
Investigational
n=268 Participants
PRESTIGE® LP Cervical Disc
|
Control
n=219 Participants
Control patients who received ACDF fusion treatment from a previous IDE trial (NCT00642876).
|
|---|---|---|
|
Arm Pain Success Rate
|
96.3 percentage of participants
|
95.0 percentage of participants
|
SECONDARY outcome
Timeframe: 24 monthsPopulation: For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable SF-36 PCS success status at 24 months, which leads to 264 subjects in the investigational group and 216 subjects in the control group.
Success rate of SF-36 Health Survey include two components: the success rate of a physical component summary (PCS) and the success rate of a mental component summary (MCS). The success of SF-36 PCS was defined as: Post Score - Pre Score \>= 0. The Success rate of SF-36 PCS is reported as the percentage of the participants who were classified as a success for SF-36 PCS.
Outcome measures
| Measure |
Investigational
n=264 Participants
PRESTIGE® LP Cervical Disc
|
Control
n=216 Participants
Control patients who received ACDF fusion treatment from a previous IDE trial (NCT00642876).
|
|---|---|---|
|
Success Rate of SF-36 PCS
|
83.7 percentage of participants
|
86.1 percentage of participants
|
SECONDARY outcome
Timeframe: 24 monthsPopulation: For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable SF-36 MCS success status at 24 months, which leads to 264 subjects in the investigational group and 216 subjects in the control group.
Success rate of SF-36 Health Survey include two components: the success rate of a physical component summary (PCS) and the success rate of a mental component summary (MCS). The success of SF-36 MCS were defined as: Post Score - Pre Score \>= 0. The Success rate of SF-36 MCS is reported as the percentage of the participants who were classified as a success for SF-36 MCS.
Outcome measures
| Measure |
Investigational
n=264 Participants
PRESTIGE® LP Cervical Disc
|
Control
n=216 Participants
Control patients who received ACDF fusion treatment from a previous IDE trial (NCT00642876).
|
|---|---|---|
|
Success Rate of SF-36 MCS
|
77.7 percentage of participants
|
69.4 percentage of participants
|
SECONDARY outcome
Timeframe: 24 monthsPopulation: For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable gait success status at 24 months, which leads to 270 subjects in the investigational group and 220 subjects in the control group.
Patient's gait was assessed by using Nurick's classification, and indicated either as normal or graded on a scale of 0 to 5. Success was defined as maintenance or improvement in the postoperative status as compared to the preoperative condition: Preoperative Score - Postoperative Score \>= 0. The gait success rate is reported as the percentage of participants who had gait success.
Outcome measures
| Measure |
Investigational
n=270 Participants
PRESTIGE® LP Cervical Disc
|
Control
n=220 Participants
Control patients who received ACDF fusion treatment from a previous IDE trial (NCT00642876).
|
|---|---|---|
|
Gait Success Rate
|
99.3 percentage of participants
|
99.5 percentage of participants
|
SECONDARY outcome
Timeframe: Time of operation, approximately 1.5 hrs.Population: For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable information for operative time, which leads to 280 subjects in the investigational group and 265 subjects in the control group.
Operative time was recorded from skin incision to wound closure.
Outcome measures
| Measure |
Investigational
n=280 Participants
PRESTIGE® LP Cervical Disc
|
Control
n=265 Participants
Control patients who received ACDF fusion treatment from a previous IDE trial (NCT00642876).
|
|---|---|---|
|
Operative Time
|
1.5 hrs
Standard Deviation 0.6
|
1.4 hrs
Standard Deviation 0.5
|
SECONDARY outcome
Timeframe: During the time of operation, approximately 1.5 hours.Population: For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable information for blood loss, which leads to 278 subjects in the investigational group and 263 subjects in the control group.
Outcome measures
| Measure |
Investigational
n=278 Participants
PRESTIGE® LP Cervical Disc
|
Control
n=263 Participants
Control patients who received ACDF fusion treatment from a previous IDE trial (NCT00642876).
|
|---|---|---|
|
Blood Loss
|
50.5 ml
Standard Deviation 73.5
|
57.5 ml
Standard Deviation 68.1
|
SECONDARY outcome
Timeframe: During the time of hospital stay, average of 1 day.Population: For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable information for hospital stay, which leads to 280 subjects in the investigational group and 265 subjects in the control group.
Outcome measures
| Measure |
Investigational
n=280 Participants
PRESTIGE® LP Cervical Disc
|
Control
n=265 Participants
Control patients who received ACDF fusion treatment from a previous IDE trial (NCT00642876).
|
|---|---|---|
|
Hospital Stay
|
1.0 days
Standard Deviation 0.5
|
1.0 days
Standard Deviation 0.5
|
SECONDARY outcome
Timeframe: 24 months post-operationPopulation: For this endpoint, the analysis consists of all subjects in the primary analysis dataset with 280 subjects in the investigational control and 265 subjects in the control group.
Secondary surgical procedures at the index level included revisions, removals, supplemental fixations and reoperations. Rate of secondary surgery at index level is reported as percentage of patients who had secondary surgeries at index level.
Outcome measures
| Measure |
Investigational
n=280 Participants
PRESTIGE® LP Cervical Disc
|
Control
n=265 Participants
Control patients who received ACDF fusion treatment from a previous IDE trial (NCT00642876).
|
|---|---|---|
|
Rate of Secondary Surgery at Index Level
|
5.0 percentage of participants
|
7.9 percentage of participants
|
SECONDARY outcome
Timeframe: Baseline and 24 months post-operationPopulation: For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable NDI score at both baseline and 24 months, which leads to 270 subjects in the investigational group and 219 subjects in the control group.
The self-administered Neck Disability Index (NDI) Questionnaire was used to assess patient neck pain and ability to function. The NDI scale ranges from 0-100. The best score is 0 (no disability) and worst is 100 (maximum disability). Change of NDI was defined as NDI at 24 month minus NDI at baseline.
Outcome measures
| Measure |
Investigational
n=270 Participants
PRESTIGE® LP Cervical Disc
|
Control
n=219 Participants
Control patients who received ACDF fusion treatment from a previous IDE trial (NCT00642876).
|
|---|---|---|
|
Change of Neck Disability Index Score From Baseline
NDI at baseline (n=280, 264)
|
55.5 units on a scale
Standard Deviation 14.7
|
56.4 units on a scale
Standard Deviation 15.9
|
|
Change of Neck Disability Index Score From Baseline
NDI at 24 months (n=270, 220)
|
15.6 units on a scale
Standard Deviation 18.3
|
22.4 units on a scale
Standard Deviation 21.5
|
|
Change of Neck Disability Index Score From Baseline
NDI change (n=270, 219)
|
-39.7 units on a scale
Standard Deviation 21.0
|
-33.9 units on a scale
Standard Deviation 21.8
|
SECONDARY outcome
Timeframe: Baseline and 24 months post-operationPopulation: For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable neck pain score at both baseline and 24 months, which leads to 270 subjects in the investigational group and 219 subjects in the control group.
Numerical rating scales were used to evaluate neck pain intensity and frequency. Patients rated their neck pain intensity on a scale from 0-10, with a score of 0 representing "no pain" and a score of 10 representing "pain as bad as it could be." Similarly, patients recorded their neck pain frequency on a scale from 0-10, with a score of 0 being "pain none of the time" and a score of 10 being "pain all of the time." The total neck pain score (0 to100) was the product of pain intensity and frequency scores. Change of neck pain score was defined as neck pain score at 24 months minus neck pain score at baseline.
Outcome measures
| Measure |
Investigational
n=270 Participants
PRESTIGE® LP Cervical Disc
|
Control
n=219 Participants
Control patients who received ACDF fusion treatment from a previous IDE trial (NCT00642876).
|
|---|---|---|
|
Change of Neck Pain Score From Baseline
Neck Pain at baseline (n=280, 264)
|
67.0 units on a scale
Standard Deviation 20.8
|
69.3 units on a scale
Standard Deviation 21.5
|
|
Change of Neck Pain Score From Baseline
Neck Pain at 24 months (n=270, 220)
|
10.6 units on a scale
Standard Deviation 19.2
|
16.6 units on a scale
Standard Deviation 24.4
|
|
Change of Neck Pain Score From Baseline
Neck Pain Change (n=270, 219)
|
-56.6 units on a scale
Standard Deviation 28.2
|
-52.1 units on a scale
Standard Deviation 28.3
|
SECONDARY outcome
Timeframe: Baseline and 24 months post-operationPopulation: For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable arm pain score at both baseline and 24 months, which leads to 268 subjects in the investigational group and 219 subjects in the control group.
Numerical rating scales were also used to evaluate arm pain intensity and frequency. Patients rated their arm pain intensity on a scale from 0-10, with a score of 0 representing "no pain" and a score of 10 representing "pain as bad as it could be." Similarly, patients recorded their arm pain frequency on a scale from 0-10, with a score of 0 being "pain none of the time" and a score of 10 being "pain all of the time." The total arm pain score (0 to 100) was the product of pain intensity and frequency scores. Change of arm pain score was defined as arm pain score at 24 months minus arm pain score at baseline.
Outcome measures
| Measure |
Investigational
n=268 Participants
PRESTIGE® LP Cervical Disc
|
Control
n=219 Participants
Control patients who received ACDF fusion treatment from a previous IDE trial (NCT00642876).
|
|---|---|---|
|
Change of Arm Pain Score From Baseline
Arm pain score at baseline (n=280, 264)
|
59.6 units on a scale
Standard Deviation 26.3
|
62.4 units on a scale
Standard Deviation 28.5
|
|
Change of Arm Pain Score From Baseline
Arm pain score at 24 months (n=268, 220)
|
8.5 units on a scale
Standard Deviation 18.3
|
14.2 units on a scale
Standard Deviation 24.3
|
|
Change of Arm Pain Score From Baseline
Arm pain score change (n=268, 219)
|
-52.0 units on a scale
Standard Deviation 31.4
|
-48.0 units on a scale
Standard Deviation 32.7
|
SECONDARY outcome
Timeframe: Baseline and 24 months post-operationPopulation: For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable PCS score at both baseline and 24 months, which leads to 264 subjects in the investigational group and 216 subjects in the control group.
The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) was used to assess general health status. The SF-36 results were summarized into two components, a physical component summary (PCS) and a mental component summary (MCS). The score for PCS was between 0 and 100, with higher scores denoting better quality of life. Change of SF-36 PCS score was defined as PCS score at 24 months minus PCS score at baseline.
Outcome measures
| Measure |
Investigational
n=264 Participants
PRESTIGE® LP Cervical Disc
|
Control
n=216 Participants
Control patients who received ACDF fusion treatment from a previous IDE trial (NCT00642876).
|
|---|---|---|
|
Change of General Health Status -- SF-36 PCS From Baseline
SF-36 PCS at baseline (n=279, 263)
|
32.2 units on a scale
Standard Deviation 7.4
|
32.0 units on a scale
Standard Deviation 7.5
|
|
Change of General Health Status -- SF-36 PCS From Baseline
SF-36 PCS at 24 months (n=265, 218)
|
46.6 units on a scale
Standard Deviation 11.4
|
44.4 units on a scale
Standard Deviation 12.0
|
|
Change of General Health Status -- SF-36 PCS From Baseline
SF-36 PCS change (n=264, 216)
|
14.3 units on a scale
Standard Deviation 11.6
|
11.9 units on a scale
Standard Deviation 10.9
|
SECONDARY outcome
Timeframe: Baseline and 24 months post-operationPopulation: For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable MCS score at both baseline and 24 months, which leads to 264 subjects in the investigational group and 216 subjects in the control group.
The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) was used to assess general health status. The SF-36 results were summarized into two components, a physical component summary (PCS) and a mental component summary (MCS). The score for MCS was between 0 and 100, with higher scores denoting better quality of life. Change of SF-36 MCS score was defined as MCS score at 24 months minus MCS score at baseline.
Outcome measures
| Measure |
Investigational
n=264 Participants
PRESTIGE® LP Cervical Disc
|
Control
n=216 Participants
Control patients who received ACDF fusion treatment from a previous IDE trial (NCT00642876).
|
|---|---|---|
|
Change of General Health Status -- SF-36 MCS From Baseline
SF-36 MCS at baseline (n=279, 263)
|
44.5 units on a scale
Standard Deviation 11.5
|
42.7 units on a scale
Standard Deviation 12.4
|
|
Change of General Health Status -- SF-36 MCS From Baseline
SF-36 MCS at 24 months (n=265, 218)
|
52.6 units on a scale
Standard Deviation 9.6
|
50.2 units on a scale
Standard Deviation 11.1
|
|
Change of General Health Status -- SF-36 MCS From Baseline
SF-36 MCS change (n=264, 216)
|
8.1 units on a scale
Standard Deviation 12.3
|
7.2 units on a scale
Standard Deviation 13.9
|
Adverse Events
Investigational
Control
Serious adverse events
| Measure |
Investigational
n=280 participants at risk
PRESTIGE® LP Cervical Disc
|
Control
n=265 participants at risk
Control patients who received ACDF fusion treatment from a previous IDE trial (NCT00642876).
|
|---|---|---|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cancer
|
0.71%
2/280 • Number of events 4 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.75%
2/265 • Number of events 2 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Cardiac disorders
Cardiac Disorders
|
3.2%
9/280 • Number of events 10 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
2.6%
7/265 • Number of events 8 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Gastrointestinal disorders
Dysphagia/Dysphonia
|
0.71%
2/280 • Number of events 3 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.38%
1/265 • Number of events 1 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Gastrointestinal disorders
Gastrointestinal
|
4.6%
13/280 • Number of events 22 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
4.5%
12/265 • Number of events 20 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Infections and infestations
Infection
|
3.9%
11/280 • Number of events 17 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
3.0%
8/265 • Number of events 8 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Nervous system disorders
Neurological
|
12.5%
35/280 • Number of events 52 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
10.2%
27/265 • Number of events 32 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory
|
2.5%
7/280 • Number of events 9 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.38%
1/265 • Number of events 1 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Injury, poisoning and procedural complications
Trauma
|
7.1%
20/280 • Number of events 22 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
3.8%
10/265 • Number of events 10 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Renal and urinary disorders
Urogenital
|
5.4%
15/280 • Number of events 20 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
1.5%
4/265 • Number of events 4 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Vascular disorders
Vascular
|
2.1%
6/280 • Number of events 7 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.00%
0/265 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Injury, poisoning and procedural complications
Wound (Non-Infectious)
|
1.8%
5/280 • Number of events 5 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
1.5%
4/265 • Number of events 4 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Respiratory, thoracic and mediastinal disorders
Dysphagia/Dysphonia
|
0.36%
1/280 • Number of events 1 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.00%
0/265 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Musculoskeletal and connective tissue disorders
Heterotopic Ossification
|
3.9%
11/280 • Number of events 13 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
3.0%
8/265 • Number of events 12 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
General disorders
Implant Events
|
1.4%
4/280 • Number of events 4 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.00%
0/265 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Musculoskeletal and connective tissue disorders
Neck and/or Arm Pain
|
13.2%
37/280 • Number of events 52 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
9.1%
24/265 • Number of events 36 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Musculoskeletal and connective tissue disorders
Non-Union
|
0.00%
0/280 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
2.3%
6/265 • Number of events 6 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Injury, poisoning and procedural complications
Spinal Events
|
0.71%
2/280 • Number of events 2 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.75%
2/265 • Number of events 2 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Musculoskeletal and connective tissue disorders
Spinal Events
|
14.3%
40/280 • Number of events 77 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
11.7%
31/265 • Number of events 54 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Nervous system disorders
Spinal Events
|
0.36%
1/280 • Number of events 1 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.75%
2/265 • Number of events 3 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Blood and lymphatic system disorders
Other
|
0.36%
1/280 • Number of events 2 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.00%
0/265 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Congenital, familial and genetic disorders
Other
|
0.36%
1/280 • Number of events 1 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.00%
0/265 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Ear and labyrinth disorders
Other
|
0.36%
1/280 • Number of events 1 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.00%
0/265 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Eye disorders
Other
|
1.1%
3/280 • Number of events 5 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.38%
1/265 • Number of events 1 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
General disorders
Other
|
0.36%
1/280 • Number of events 1 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.75%
2/265 • Number of events 2 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Immune system disorders
Other
|
0.36%
1/280 • Number of events 1 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
1.1%
3/265 • Number of events 3 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Injury, poisoning and procedural complications
Other
|
3.2%
9/280 • Number of events 9 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
1.1%
3/265 • Number of events 3 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Investigations
Other
|
1.1%
3/280 • Number of events 5 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.38%
1/265 • Number of events 2 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Metabolism and nutrition disorders
Other
|
0.36%
1/280 • Number of events 1 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.00%
0/265 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Musculoskeletal and connective tissue disorders
Other
|
0.00%
0/280 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
1.9%
5/265 • Number of events 6 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Other
|
1.1%
3/280 • Number of events 3 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.38%
1/265 • Number of events 1 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Nervous system disorders
Other
|
1.1%
3/280 • Number of events 3 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.75%
2/265 • Number of events 3 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Pregnancy, puerperium and perinatal conditions
Other
|
0.00%
0/280 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.38%
1/265 • Number of events 1 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Psychiatric disorders
Other
|
2.1%
6/280 • Number of events 8 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
1.9%
5/265 • Number of events 6 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Surgical and medical procedures
Other
|
1.1%
3/280 • Number of events 4 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.75%
2/265 • Number of events 2 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Vascular disorders
Other
|
0.36%
1/280 • Number of events 1 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.00%
0/265 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Ear and labyrinth disorders
Other Pain
|
0.36%
1/280 • Number of events 1 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.00%
0/265 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Eye disorders
Other Pain
|
0.36%
1/280 • Number of events 1 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.00%
0/265 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
General disorders
Other Pain
|
1.1%
3/280 • Number of events 3 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
1.1%
3/265 • Number of events 4 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Injury, poisoning and procedural complications
Other Pain
|
3.6%
10/280 • Number of events 11 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
2.3%
6/265 • Number of events 7 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Musculoskeletal and connective tissue disorders
Other Pain
|
9.6%
27/280 • Number of events 38 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
6.0%
16/265 • Number of events 21 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Nervous system disorders
Other Pain
|
3.6%
10/280 • Number of events 12 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.75%
2/265 • Number of events 2 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Respiratory, thoracic and mediastinal disorders
Other Pain
|
0.36%
1/280 • Number of events 1 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.00%
0/265 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
Other adverse events
| Measure |
Investigational
n=280 participants at risk
PRESTIGE® LP Cervical Disc
|
Control
n=265 participants at risk
Control patients who received ACDF fusion treatment from a previous IDE trial (NCT00642876).
|
|---|---|---|
|
Injury, poisoning and procedural complications
Anatomical/technical difficulty
|
0.71%
2/280 • Number of events 2 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.00%
0/265 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cancer
|
0.36%
1/280 • Number of events 1 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.00%
0/265 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Cardiac disorders
Cardiac Disorders
|
2.9%
8/280 • Number of events 11 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
4.2%
11/265 • Number of events 12 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Gastrointestinal disorders
Dysphagia/Dysphonia
|
6.8%
19/280 • Number of events 21 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
7.9%
21/265 • Number of events 22 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Nervous system disorders
Dysphagia/Dysphonia
|
0.36%
1/280 • Number of events 1 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.00%
0/265 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Respiratory, thoracic and mediastinal disorders
Dysphagia/Dysphonia
|
2.5%
7/280 • Number of events 7 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.00%
0/265 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Gastrointestinal disorders
Gastrointestinal
|
8.9%
25/280 • Number of events 33 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
11.3%
30/265 • Number of events 48 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Musculoskeletal and connective tissue disorders
Heterotopic Ossification
|
5.7%
16/280 • Number of events 18 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
2.6%
7/265 • Number of events 9 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
General disorders
Implant Events
|
4.3%
12/280 • Number of events 13 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
1.9%
5/265 • Number of events 5 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Infections and infestations
Infection
|
10.0%
28/280 • Number of events 40 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
8.3%
22/265 • Number of events 29 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Musculoskeletal and connective tissue disorders
Neck and/or Arm Pain
|
44.6%
125/280 • Number of events 223 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
42.6%
113/265 • Number of events 177 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Nervous system disorders
Neurological
|
41.4%
116/280 • Number of events 190 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
34.7%
92/265 • Number of events 185 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Musculoskeletal and connective tissue disorders
Non-Union
|
0.00%
0/280 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
9.1%
24/265 • Number of events 24 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Blood and lymphatic system disorders
Other
|
0.36%
1/280 • Number of events 1 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
1.5%
4/265 • Number of events 4 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Congenital, familial and genetic disorders
Other
|
0.00%
0/280 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.38%
1/265 • Number of events 1 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Ear and labyrinth disorders
Other
|
1.8%
5/280 • Number of events 6 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.38%
1/265 • Number of events 2 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Endocrine disorders
Other
|
0.71%
2/280 • Number of events 3 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.75%
2/265 • Number of events 2 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Eye disorders
Other
|
1.1%
3/280 • Number of events 3 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.75%
2/265 • Number of events 2 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Gastrointestinal disorders
Other
|
0.00%
0/280 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.38%
1/265 • Number of events 1 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
General disorders
Other
|
3.9%
11/280 • Number of events 12 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
4.2%
11/265 • Number of events 14 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Immune system disorders
Other
|
2.1%
6/280 • Number of events 7 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.38%
1/265 • Number of events 1 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Infections and infestations
Other
|
0.00%
0/280 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.38%
1/265 • Number of events 1 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Injury, poisoning and procedural complications
Other
|
4.6%
13/280 • Number of events 14 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
1.5%
4/265 • Number of events 4 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Investigations
Other
|
5.4%
15/280 • Number of events 16 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
2.3%
6/265 • Number of events 7 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Metabolism and nutrition disorders
Other
|
1.4%
4/280 • Number of events 4 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
1.1%
3/265 • Number of events 3 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Musculoskeletal and connective tissue disorders
Other
|
6.1%
17/280 • Number of events 19 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
3.0%
8/265 • Number of events 9 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Other
|
0.36%
1/280 • Number of events 1 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.00%
0/265 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Nervous system disorders
Other
|
1.8%
5/280 • Number of events 6 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
4.5%
12/265 • Number of events 14 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Psychiatric disorders
Other
|
6.1%
17/280 • Number of events 21 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
6.0%
16/265 • Number of events 23 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Renal and urinary disorders
Other
|
0.00%
0/280 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.38%
1/265 • Number of events 1 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Reproductive system and breast disorders
Other
|
0.71%
2/280 • Number of events 2 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.38%
1/265 • Number of events 1 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Skin and subcutaneous tissue disorders
Other
|
4.3%
12/280 • Number of events 13 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
3.8%
10/265 • Number of events 11 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Social circumstances
Other
|
0.71%
2/280 • Number of events 2 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.00%
0/265 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Surgical and medical procedures
Other
|
0.36%
1/280 • Number of events 1 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.75%
2/265 • Number of events 2 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Vascular disorders
Other
|
0.36%
1/280 • Number of events 1 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.00%
0/265 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Blood and lymphatic system disorders
Other Pain
|
0.00%
0/280 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.75%
2/265 • Number of events 2 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Ear and labyrinth disorders
Other Pain
|
0.36%
1/280 • Number of events 1 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.00%
0/265 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Eye disorders
Other Pain
|
0.36%
1/280 • Number of events 1 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.38%
1/265 • Number of events 1 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Gastrointestinal disorders
Other Pain
|
0.36%
1/280 • Number of events 1 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.38%
1/265 • Number of events 1 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
General disorders
Other Pain
|
2.1%
6/280 • Number of events 6 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
4.9%
13/265 • Number of events 13 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Injury, poisoning and procedural complications
Other Pain
|
6.1%
17/280 • Number of events 23 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
6.0%
16/265 • Number of events 20 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Metabolism and nutrition disorders
Other Pain
|
0.71%
2/280 • Number of events 2 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.38%
1/265 • Number of events 1 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Musculoskeletal and connective tissue disorders
Other Pain
|
31.4%
88/280 • Number of events 121 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
30.2%
80/265 • Number of events 122 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Nervous system disorders
Other Pain
|
15.4%
43/280 • Number of events 50 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
12.1%
32/265 • Number of events 35 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Respiratory, thoracic and mediastinal disorders
Other Pain
|
1.8%
5/280 • Number of events 5 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.75%
2/265 • Number of events 2 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Skin and subcutaneous tissue disorders
Other Pain
|
0.36%
1/280 • Number of events 1 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.00%
0/265 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory
|
7.1%
20/280 • Number of events 25 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
6.0%
16/265 • Number of events 22 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Musculoskeletal and connective tissue disorders
Spinal Events
|
17.9%
50/280 • Number of events 91 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
10.2%
27/265 • Number of events 42 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Spinal Events
|
0.00%
0/280 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.38%
1/265 • Number of events 1 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Nervous system disorders
Spinal Events
|
0.36%
1/280 • Number of events 1 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
0.38%
1/265 • Number of events 1 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Injury, poisoning and procedural complications
Trauma
|
15.7%
44/280 • Number of events 49 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
11.3%
30/265 • Number of events 34 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Renal and urinary disorders
Urogenital
|
5.7%
16/280 • Number of events 22 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
2.3%
6/265 • Number of events 7 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Vascular disorders
Vascular
|
2.1%
6/280 • Number of events 6 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
1.5%
4/265 • Number of events 4 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
|
Injury, poisoning and procedural complications
Wound(Non-Infectious)
|
7.1%
20/280 • Number of events 29 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
3.4%
9/265 • Number of events 9 • up to 24 months
The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place
Restriction type: LTE60